PT1169063E - Tratamento de infeccao intracelular - Google Patents

Tratamento de infeccao intracelular

Info

Publication number
PT1169063E
PT1169063E PT00919042T PT00919042T PT1169063E PT 1169063 E PT1169063 E PT 1169063E PT 00919042 T PT00919042 T PT 00919042T PT 00919042 T PT00919042 T PT 00919042T PT 1169063 E PT1169063 E PT 1169063E
Authority
PT
Portugal
Prior art keywords
agent
target cell
phage
intracellular
combating
Prior art date
Application number
PT00919042T
Other languages
English (en)
Inventor
Vladimir Artymovich Pasechnik
Allen Douglas Glen Roberts
Richard James Sharp
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Publication of PT1169063E publication Critical patent/PT1169063E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT00919042T 1999-04-09 2000-04-10 Tratamento de infeccao intracelular PT1169063E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9908195.2A GB9908195D0 (en) 1999-04-09 1999-04-09 Treatment of intracellular infection

Publications (1)

Publication Number Publication Date
PT1169063E true PT1169063E (pt) 2004-10-29

Family

ID=10851274

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00919042T PT1169063E (pt) 1999-04-09 2000-04-10 Tratamento de infeccao intracelular

Country Status (12)

Country Link
US (1) US6660264B1 (pt)
EP (1) EP1169063B1 (pt)
JP (1) JP2002541217A (pt)
AT (1) ATE270115T1 (pt)
AU (1) AU772115B2 (pt)
CA (1) CA2372078A1 (pt)
DE (1) DE60011880T2 (pt)
DK (1) DK1169063T3 (pt)
ES (1) ES2220451T3 (pt)
GB (1) GB9908195D0 (pt)
PT (1) PT1169063E (pt)
WO (1) WO2000061190A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221713A1 (en) * 2000-10-25 2002-05-06 Intercell Biomedizinische Forschulungs- Und Entwicklungs Ag Modified phage, comprising a non-lytic modification and expressing a kil-gene
ATE333288T1 (de) * 2001-05-15 2006-08-15 Faulk Pharmaceuticals Inc Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
GB0115385D0 (en) * 2001-06-22 2001-08-15 Regma Biotechnologies Ltd Novel preparation
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
JP4959110B2 (ja) * 2002-02-07 2012-06-20 マサチューセッツ インスティテュート オブ テクノロジー 抗病原体治療
GB0205786D0 (en) * 2002-03-12 2002-04-24 Regma Bio Technologies Ltd Novel Composition
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
DE10235967B4 (de) * 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
WO2004087924A2 (en) * 2003-03-31 2004-10-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for delivery of substances to intracellular microorganisms
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
AU2005214287A1 (en) * 2004-02-20 2005-09-01 Genesis Research And Development Corporation Limited Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
EP2102338B1 (en) * 2006-12-12 2010-07-21 MorphoSys AG Internalization
US8619257B2 (en) * 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
EA034333B1 (ru) 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829266A (en) 1957-03-20 1960-03-02 Biogena A method of manufacturing bacteriophages in solid dry form
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU5356490A (en) 1989-04-03 1990-11-05 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
ES2078521T3 (es) 1990-05-18 1995-12-16 Boehringer Ingelheim Int Nuevos conjugados de proteina-polication.
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8740491A (en) 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
ATE431364T1 (de) 1991-03-01 2009-05-15 Dyax Corp Inhibitoren der menschlichen elastase von neutrophilen
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
DE4115038A1 (de) 1991-05-08 1992-11-12 Genentech Inc Neue konjugate, bestehend aus einem glykoprotein und einer nukleinsaeure-bindenden substanz
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5922859A (en) 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
AU679228B2 (en) 1993-04-27 1997-06-26 Symbiotech, Inc. Method of detecting compounds utilizing chemically modified lambdoid bacteriophage
DE4335025A1 (de) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
AU699322B2 (en) 1994-04-05 1998-12-03 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US6284880B1 (en) 1994-05-30 2001-09-04 Boehringer Ingelheim International Gmbh Chicken embryo lethal orphan (CELO) virus GAM-1
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
GB9412844D0 (en) 1994-06-27 1994-08-17 Medical Res Council Improvements in or relating to therapeutic methods
US5736388A (en) 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
WO1997023608A1 (en) 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
CA2251724A1 (en) 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
WO1998005344A1 (en) 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
WO1999010485A1 (en) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Methods using phage display for selecting internalizing ligands for gene delivery
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
DE19909770A1 (de) * 1999-03-05 2000-09-07 Werner Lubitz Bakterienghosts als Träger- und Targetingvehikel

Also Published As

Publication number Publication date
ES2220451T3 (es) 2004-12-16
DK1169063T3 (da) 2004-11-01
DE60011880T2 (de) 2005-08-25
AU772115B2 (en) 2004-04-08
US6660264B1 (en) 2003-12-09
ATE270115T1 (de) 2004-07-15
DE60011880D1 (de) 2004-08-05
GB9908195D0 (en) 1999-06-02
EP1169063A2 (en) 2002-01-09
WO2000061190A2 (en) 2000-10-19
JP2002541217A (ja) 2002-12-03
AU3979800A (en) 2000-11-14
EP1169063B1 (en) 2004-06-30
WO2000061190A3 (en) 2001-03-01
CA2372078A1 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
PT1169063E (pt) Tratamento de infeccao intracelular
YU4602A (sh) Farmaceutske formulacije zaštićene od dejstva mikroorganizama
WO2001092288A3 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
CA2292359A1 (en) Novel azalides and methods of making same
HK1094320A1 (en) Antiseptic compositions, methods and systems
TR200003170T2 (tr) MRS inhibitörleri ve bakterisid olarak kullanılan quinolone'lar
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
MY125356A (en) Moxifloxacin/sodium chloride formulation
GEP20053429B (en) 3-Aminoquinazolin-2,4-Dione, Pharmaceutical Composition Containing Them and Use Thereof as Antibacterial Agents
GR1003560B (el) Σκευασματα τροποποιημενης απελευθερωσης αμοξυκιλλινης και κλαβουλανικου καλιου
MXPA03010761A (es) Combinaciones farmaceuticas.
DK1037650T3 (da) Præparater til behandling af Staphylococcus aureus-infektioner
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
MXPA03002909A (es) Compuestos quimicos.
ATE242630T1 (de) Beladene bakterienghosts als träger- und targetingvehikel
MX2007008585A (es) Compuestos peptidicos.
WO2001089317A3 (en) Dietary aids and methods of use thereof
GEP20012423B (en) Composition for Organ Cryopreservation and Treatment of Viral and Bacterial Infections
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
WO2002049633A3 (en) Use of amidoamines to treat or prevent acanthamoeba and fungal infections
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.
HUP0202888A2 (hu) Xenogén oligo- és/vagy poliribonukleotidokat tartalmazó gyógyszerkészítmény
EA200300725A1 (ru) Соединение азола в качестве противогрибковых средств